Navigation Links
Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
Date:4/24/2008

Final Decision from European Commission Expected by Mid-2008

COLLEGEVILLE, Pa. and TARRYTOWN, N.Y., April 24 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), today announced that the companies have received a positive opinion for RELISTOR(TM) (methylnaltrexone bromide) subcutaneous injection from the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA). The companies are seeking the approval of RELISTOR in Europe for the treatment of opioid-induced constipation in advanced-illness patients who are receiving palliative care when response to usual laxative therapy has not been sufficient.

The CHMP is responsible for reviewing medicinal product applications for safety, quality and efficacy. The CHMP's positive opinion for RELISTOR will now be forwarded to the European Commission for a final decision, which is anticipated by mid-year.

RELISTOR, administered via subcutaneous injection, is a peripherally acting mu-opioid receptor antagonist that decreases the constipating effects of opioid pain medications in the gastrointestinal tract without affecting their ability to relieve pain.

About the Subcutaneous RELISTOR Clinical Investigational Program

In March 2007, Progenics submitted a New Drug Application for subcutaneous RELISTOR for the treatment of opioid-induced constipation (OIC) in patients receiving palliative care to the U.S. Food
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Wyeth to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
2. Wyeth Sets Webcast And Conference Call For 2008 First Quarter Earnings
3. Wyeth To Appeal Arkansas Hormone Therapy Trial Verdicts
4. Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
5. Wyeth Announces Executive Change in Finance Organization
6. Wyeth Announces Election of Timothy P. Cost as Senior Vice President, Corporate Affairs
7. Wyeth to Present at the Merrill Lynch 2008 Global Pharmaceutical, Biotechnology and Medical Device Conference
8. Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
9. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
10. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
11. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 The global companion diagnostics ... 2019. It is expected to grow at a ... was valued at $1.8 billion in 2013, according ... Research. , For more information regarding analysis details ... The research report, titled “Companion Diagnostics Market (Breast ...
(Date:8/29/2014)... 29, 2014 According to a new market ... global orthobiologics market was valued at USD 3,754.6 million in ... 5,519.9million in 2019at a CAGR of 5.9% from 2013 to ... and above is afflicted by bone and joint disorders, and ... 2020. This has and will continue to increase the demand ...
(Date:8/29/2014)... August 29, 2014 Pittcon is pleased ... and colleague Koichiro Matsuda, Horiba Scientific, have organized a ... 5, 2014. JASIS , Asia’s largest analytical and ... in Makuhari Messe, Japan. , The four speakers ... Bioanalysis from Single Molecules to Single Cells” will present ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" ... reported financial results for the six months ended ... expressed in Canadian dollars and presented under International ... 2014 Highlights , Announced top-line results ... primary endpoint for subjects enrolled in the Phase ...
Breaking Biology Technology:Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4
... on nanomedical applications in diagnostics, imaging, and ... ... Cleveland Clinic,Lerner Research Institute, and Case Western Reserve University today,announced the ... of nanoparticles for diagnostics, imaging and therapeutics,to improve medical treatment and ...
... Arete Therapeutics Inc., a,privately-held biopharmaceutical company developing ... appointment of,James Sabry, M.D., Ph.D., as president and ... advisor and member of the board of directors,since ... the position of,president and chief executive officer, who ...
... ARBOR, Mich., July 8 NanoBio(R) Corp., a,biopharmaceutical ... prevent and treat infectious diseases, today announced the,appointment ... of directors., Dr. Dubin currently serves as ... leading healthcare and biotechnology investment banking firm., ...
Cached Biology Technology:NanoMedicine Summit Returns to Cleveland, September 25-26 2NanoMedicine Summit Returns to Cleveland, September 25-26 3NanoMedicine Summit Returns to Cleveland, September 25-26 4Arete Therapeutics Names James Sabry, M.D., Ph.D., President and Chief Executive Officer 2Daniel B. Dubin, M.D., Joins NanoBio Corp.'s Board of Directors 2
(Date:8/29/2014)... Ebola researcher from the University of Texas Medical Branch at ... three monoclonal antibodies can completely protect monkeys against a lethal ... at a time when the disease is severe. , Thomas ... for Nature discussing advances in Ebola treatment research. ... among the most deadly of pathogens, with fatality rates of ...
(Date:8/29/2014)... climatic shifts over the last 120,000 years may ... team of researchers led by City College of ... new biodiversity metric called "phylogeographic endemism." , It ... within species is restricted in geographical space. , ... 14 other researchers from institutions in Brazil, Australia ...
(Date:8/29/2014)... number of connections in transcription factor networks (TFNs) to ... study published in PLOS Computational Biology in ... contributes to a network,s resilience against mutations. , ... of TFN models has a greater effect on robustness ... assortativity," said Dov A. Pechenick, PhD, lead author and ...
Breaking Biology News(10 mins):Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2CCNY team defines new biodiversity metric 2Assortativity signatures of transcription factor networks contribute to robustness 2
... researchers has studied the changes in the make-up of ... malacological fauna are a good indicator of forest recovery. ... that post-fire forestry operations that do not harm these ... of the soil and vegetation structure. The researchers ...
... WI, February 15, 2010 -- Agricultural nonpoint source ... leading sources of pollution in rivers and water ... are making concerted efforts to reduce these pollutions ... As promising and effective BMPs, vegetated buffers are ...
... DNA from royal mummies, research findings suggest that malaria and ... Egyptian pharaoh King Tutankhamun, with other results appearing to identify ... mother, according to a study in the February 17 issue ... B.C.) of the New Kingdom was one of the most ...
Cached Biology News:Presence of snails points to forest recovery 2A review of vegetated buffer efficacy 2Study examines family lineage of King Tut, his possible cause of death 2Study examines family lineage of King Tut, his possible cause of death 3Study examines family lineage of King Tut, his possible cause of death 4Study examines family lineage of King Tut, his possible cause of death 5
mu Opioid Receptor splice variant Immunogen: Synthetic peptide corresponding to residues K S C M D R G M R N L L P D D G P R Q E of Mu Opioid Receptor. Storage: -20 C, Avoid Freeze/Thaw Cycle...
Rac1/2/3 (L129) Antibody Shipping Temperature: HOT Storage Temperature: -20C...
In plasmid or lambda vector. Please inquire for more details!...
ANTI-RAT ADHESION MARKERS, CDs, CYTOKINES, ETC Rat ICAM PE - Mouse IgG1...
Biology Products: